Interest of FDG-PET in the Management of Mantle Cell Lymphoma

Frontiers in Medicine

article

Clément Bailly¹  Thomas Carlier¹  Cyrille Touzeau³  Nicolas Arlicot¹  Françoise Kraeber-Bodéré¹  Steven Le Gouill³  Caroline Bodet-Milin¹ 

[1] Université d'Angers, Université de Nantes;Department of Nuclear Medicine;Department of Hematology

关键词: mantle cell lymphoma;    FDG-PET;    staging;    therapeutic evaluation;    SUV;   

DOI  :  10.3389/fmed.2019.00070

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

FDG-PET changed response assessment and therapy strategy in diffuse large B-cell lymphoma and Hodgkin disease lymphoma. The value of FDG-PET evaluation in MCL has not been extensively studied and a recent expert consensus highlighted the need for more studies addressing this question. Data of the literature show the value of FDG-PET at baseline in patients with MCL, underlining the good sensitivity of this examination for the initial staging of this pathology, but also the potential impact of semi-quantitative analysis in this indication. The determination of SUVmax at diagnosis might indeed provide important prognostic information. Some studies also suggest the potential value of early and end-of-treatment metabolic assessment in MCL, but these results need to be validated in standardized prospective studies. These results also underlie the need to integrate FDG-PET results into MCL treatment strategy to improve disease management in identifying patients who might benefit from more intensive therapy.

【 授权许可】

CC BY